SCHEMBL23309709

SCHEMBL23309709

N#Cc1ccccc1NC(=O)c1cc(F)nc(F)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHB3 P54753 1/20 0.50
▸ KMT2A Q03164 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.45
▸ GAA P10253 3/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ RAB9A P51151 3/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ THRB P10828 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ PDK1 Q15118 1/20 0.43
▸ PDK2 Q15119 1/20 0.43
▸ PDK3 Q15120 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23309734 0.81 RAB9A (0.54) EPHB3KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL23309509 0.80 TP53 (0.51) KMT2ASMN1; SMN2MEN1MAPTTSHR
SCHEMBL23309603 0.80 CYP1A2 (0.56) EPHB3KMT2ASMN1; SMN2MEN1RAB9A
SCHEMBL23309697 0.80 HTT (0.56) KMT2ASMN1; SMN2MEN1MAPTMAPK1
SCHEMBL23309498 0.79 MEN1 (0.55) KMT2ASMN1; SMN2MEN1MAPTKDM4E
SCHEMBL23309490 0.76 GAA (0.51) KMT2ASMN1; SMN2MEN1KDM4EGAA
SCHEMBL23309521 0.76 GRM5 (0.51) KMT2AMEN1MAPTTSHRKDM4E
SCHEMBL23309512 0.76 HTT (0.57) KMT2ASMN1; SMN2MEN1MAPTGAA
SCHEMBL23309595 0.75 EPHB3 (0.47) EPHB3KMT2ASMN1; SMN2MEN1MAPT
SCHEMBL23309730 0.74 KMT2A (0.47) KMT2ASMN1; SMN2MEN1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210120817-A1 PLANT DISEASE CONTROL AGENT MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-04-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210120817-A1 PLANT DISEASE CONTROL AGENT BROX, ALG1, CTRL EPHB3 4222/4885KMT2A 2360/4885SMN1; SMN2 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback